These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35892670)

  • 21. Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens.
    Busca C; Sánchez-Conde M; Rico M; Rosas M; Valencia E; Moreno A; Moreno V; Martín-Carbonero L; Moreno S; Pérez-Valero I; Bernardino JI; Arribas JR; González J; Olveira A; Castillo P; Abadía M; Guerra L; Mendez C; Montes ML
    Open Forum Infect Dis; 2022 Jul; 9(7):ofac279. PubMed ID: 35873289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of Nonalcoholic Fatty Liver Disease and Subclinical Atherosclerosis Among Young Mexican Americans.
    Gill C; Vatcheva KP; Pan JJ; Smulevitz B; McPherson DD; Fallon M; McCormick JB; Fisher-Hoch SP; Laing ST
    Am J Cardiol; 2017 Jun; 119(11):1717-1722. PubMed ID: 28395890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
    Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
    Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Study of Correlation between Non Alcoholic Fatty Liver Disease and Carotid Atherosclerosis.
    Sagar A; L R; Farheen SA
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin Resistance, but Not Obstructive Sleep Apnea Is Associated with Hepatic Steatosis in Chinese Patients with Severe Obesity.
    Zhu C; Tang S; Xiao J; Zhang Y; Sun L; Zhang J; Ding L; Liu M
    Obes Facts; 2023; 16(4):344-355. PubMed ID: 36854279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic steatosis in obese Chinese children.
    Chan DF; Li AM; Chu WC; Chan MH; Wong EM; Liu EK; Chan IH; Yin J; Lam CW; Fok TF; Nelson EA
    Int J Obes Relat Metab Disord; 2004 Oct; 28(10):1257-63. PubMed ID: 15278103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in Obese Non-Alcoholic Fatty Liver Disease (NAFLD) Patients.
    Damjanovska S; Karb DB; Tripathi A; Asirwatham J; Delozier S; Perez JA; Falck-Ytter Y; Cohen S
    Cureus; 2022 Sep; 14(9):e29445. PubMed ID: 36299964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study.
    Seeberg KA; Hofsø D; Borgeraas H; Grimnes JO; Fatima F; Seeberg LT; Kvan NP; Svanevik M; Hertel JK; Hjelmesæth J
    BMC Gastroenterol; 2022 Nov; 22(1):448. PubMed ID: 36336684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study.
    Lee HH; Cho Y; Choi YJ; Huh BW; Lee BW; Kang ES; Park SW; Cha BS; Lee EJ; Lee YH; Huh KB
    Cardiovasc Diabetol; 2020 Jun; 19(1):81. PubMed ID: 32534588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age, abdominal obesity, and glycated hemoglobin are associated with carotid atherosclerosis in type 2 diabetes patients with nonalcoholic fatty liver disease.
    Silaghi CA; Silaghi H; Crăciun AE; Fărcaș A; Colosi HA; Cosma DT; Pais R; Hâncu N; Georgescu CE
    Med Ultrason; 2015 Sep; 17(3):300-7. PubMed ID: 26343077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between non-alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community.
    Tan EC; Tai MS; Chan WK; Mahadeva S
    JGH Open; 2019 Apr; 3(2):117-125. PubMed ID: 31061886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study.
    Chung SM; Moon JS; Yoon JS; Won KC; Lee HW
    J Trace Elem Med Biol; 2020 Dec; 62():126601. PubMed ID: 32634767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old.
    Zheng J; Zhou Y; Zhang K; Qi Y; An S; Wang S; Zhao X; Tang YD
    BMC Cardiovasc Disord; 2018 Jul; 18(1):147. PubMed ID: 30012085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
    Carretero-Gómez J; Carrasco-Sánchez FJ; Fernández-Rodríguez JM; Casado-Escribano P; Miramontes-González JP; Seguí-Ripoll JM; Ena J; Arévalo-Lorido JC;
    Rev Clin Esp (Barc); 2023 Mar; 223(3):134-143. PubMed ID: 36549643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.
    Başar O; Akbal E; Köklü S; Tuna Y; Koçak E; Başar N; Tok D; Erbiş H; Senes M
    Herz; 2013 Jun; 38(4):417-22. PubMed ID: 23324907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAI-1 levels are related to insulin resistance and carotid atherosclerosis in subjects with familial combined hyperlipidemia.
    Carratala A; Martinez-Hervas S; Rodriguez-Borja E; Benito E; Real JT; Saez GT; Carmena R; Ascaso JF
    J Investig Med; 2018 Jan; 66(1):17-21. PubMed ID: 28822973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.